This report evaluates the analytical validity, clinical validity, and clinical utility of the CANCERPLEX test. According to the laboratory, the test is intended to identify patients who are most likely to respond to immune checkpoint inhibition and detect the presence of human papilloma virus (HPV)/Epstein-Barr virus (EBV) viral integration, which may impact treatment decisions.

If you have a Hayes login, click here to view the full report on the Knowledge Center.